These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16159044)

  • 1. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.
    Cheetham TC; Chan J; Benson V; Richmond C; Levin E; Campen D
    Am J Manag Care; 2005 Sep; 11(9):546-52. PubMed ID: 16159044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization.
    Billups SJ; Plushner SL; Olson KL; Koehler TJ; Kerzee J
    J Manag Care Pharm; 2005 Oct; 11(8):681-6. PubMed ID: 16194132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
    Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C
    Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarketing analysis of lovastatin use in the VA Northern California System of Clinics: a retrospective, computer-based study.
    Swislocki AL; Lin K; Cogburn D; Fann KY; Khuu DT; Noth RH
    Am J Manag Care; 1997 Oct; 3(10):1537-45. PubMed ID: 10178460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.
    Pedersen TR; Berg K; Cook TJ; Faergeman O; Haghfelt T; Kjekshus J; Miettinen T; Musliner TA; Olsson AG; Pyörälä K; Thorgeirsson G; Tobert JA; Wedel H; Wilhelmsen L
    Arch Intern Med; 1996 Oct; 156(18):2085-92. PubMed ID: 8862101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness and tolerability of simvastatin in subjects with primary hypercholesterolemia. Multicenter study].
    Finardi G; Perani G; Tramarin R; Ricciardi R; Falaschi F; Franco C
    Clin Ter; 1993 Mar; 142(3):225-33. PubMed ID: 8482062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
    Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison Company) compared to simvastatin (Zocor) in hypercholesterolemic subjects.
    Assawawitoontip S; Wiwanitkit V
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S118-24. PubMed ID: 12188401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of three statins at lower maintenance doses.
    Carr-Lopez S; Exstrum T; Morse T; Shepherd M; Bush AC
    Clin Ther; 1999 Feb; 21(2):331-9. PubMed ID: 10211536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet.
    Ose L; Johnson-Levonas A; Reyes R; Lin J; Shah A; Tribble D; Musliner T;
    Int J Clin Pract; 2007 Sep; 61(9):1469-80. PubMed ID: 17655686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.